Home > Company > Development & Awards

Date		Event
11/2009		Together with world’s top gene synthesis companies GENEART forms the International Gene Synthesis Consortium (IGSC) and establishes tough biosecurity screening protocol to enhance biosecurity.
09/2009		GENEART is new research partner of the PolyModE joint project supported by the EU Commission.
08/2009		Production capacities increase to 3 million base pairs per month.
07/2009		Actelion Pharmaceuticals Ltd. chooses GENEART as exclusive supplier for DNA engineering & processing services.
06/2009		GENEART supports the UK HIV Vaccine Consortium (UK HVC) in developing a DNA vaccine candidate against HIV.
06/2009		Max Planck Institute for Molecular Genetics places major contract within the BMBF Joined Project “IG Mutanom”.
05/2009		GENEART synthesizes genes for swine flu vaccine in record speed for pharma top 10 company, the Robert Koch Institute and several other customers.
12/2008		Successful collaboration with Morphosys on the HuCAL PLATINUM® project. High quality DNA components optimized and synthesized by GENEART enable increased diversity of antibody library and improved expression levels of identified antibodies.
11/2008		Wellcome Trust Sanger Institute awards major contract on the synthesis of up to 600 genes. The genes will be used to identify mechanisms involved in defined genetic and infectious diseases.
9/2008		Foundation of GENEART Inc. on the U.S. Amercian West Coast to improve customer support in one of the world´s largest biotech clusters in the San Francisco Bay Area.
7/2008		BMBF awards a grant of approximately EUR 0.2M for advancements in targeted protein design of vaccine candidates.
7/2008		US National Cancer Institute (part of the National Institutes of Health - NIH) extends gene synthesis contract by USD 2.7M for 2008.
6/2008		Cooperation with Boehringer Ingelheim to offer system solutions from the design to the production of DNA-based pharmaceutical agents for research, development and clinical trials in every quantity and in highest quality up to cGMP.
5/2008		Technology and distribution partnership with QIAGEN to commercialize optimized, synthetic, mammalian, standard genes via QIAGEN’s web portal GeneGlobe.
4/2008		Award of patent family EP 1240333 “Genome of the HIV-1 inter-subtype (C/B') and use thereof” in Europe and in the United States for successfully tested HIV vaccine in clinical phase I by EuroVacc Foundation. Further clinical Phase I/II studies of the licensed gene sequences have been initiated by EuroVacc in 2008.
01/2008		GENEART supports the J. Craig Venter Institute to create the first synthetic bacterial genome.
12/2007		Production capacities increase to 2 million base pairs per month. The number of employees grows to more than 190.
01/2007		Worldwide largest gene synthesis contract is awarded to GENEART by the US National Cancer Institute (part of NIH) with an order volume of several million USD.
12/2006		Production capacities increase to 1 million base pairs per month.
11/2006		BMBF (German Federal Ministry of Education and Research) awards research grant of EUR 1.5M to develop new technology platform for directed evolution of proteins.
05/2006		IPO at the Entry Standard of Frankfurt Stock Exchange
02/2006		Production capacities increase to 0.5 Mio base pairs per month.
11/2005		Foundation of GENEART Inc. in Canada
07/2005		GENEART welcomes the 50th employee
01/2005		The GENEART gene synthesis process is fully DIN EN ISO 9001 certified by TÜV Süd Management Service.
07/2004		Multi-national HIV vaccine clinical trial (EUROVACC) uses genes produced and designed by GENEART.
09/2002		Second Round of Financing Lead investor: EquiNet Venture Partners AG Co-investor: S-Refit AG, tbg, Bayern Kapital
06/2001		Launch of proprietary gene sequence design software GeneOptimizer®
10/2000		Awarded BMBF grant (BioChance-Program) for gene synthesis project
05/2000		First Round of Financing Lead investor: S-Refit AG Co-investor: tbg, Bayern Kapital
05/2000		Market Entry of GENEART
11/1999		Foundation of GENEART

Date		Event
2009		GENEART is a landmark in the “365 Landmarks in the Land of Ideas” contest. The initiative has partnered with Deutsche Bank to run the contest. Patron is Germany’s Federal President Horst Köhler.
2008		GENEART wins “European Biotechnica Award”
2007 2008		GENEART reaches contest finals “Entrepreneur of the Year"
2006		The F.A.Z Institute and Infraserv Hoechst recognize GENEART with the “STEP Award” for high growth companies. The award includes EUR 100,000 in prize money.
2006 2007 2009		GENEART is recognized as one of Bavaria’s fastest growing enterprises and receives the “BAYERNS BEST 50” business award
2005 2006 2007 2008		GENEART is honored with the “Deloitte Technology Fast 500” Award as one of the 500 fastest growing technology companies in Europe
2005 2006 2007 2008		GENEART is honored with the “Deloitte Technology Fast 50” Award as one of the 50 fastest growing technology companies in Germany
2004		GENEART is awarded with the “Potential Innovation 2004 prize” by DIHK and Financial Times Deutschland
2003		GENEART is recognized by “German Founders’ Award” („Deutscher Gründerpreis“)
2003		GENEART is honoured with the “Young Enterprise Award of Bavaria” (“Bayerischer Gründerpreis”)